相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The potential markers of endocrine resistance among HR+/HER2+breast cancer patients
K. Chen et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Targeting CDK4/6 pathways and beyond in breast cancer
Domen Ribnikar et al.
BREAST (2019)
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2-advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.
Robert Hugh Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC).
Carey K. Anders et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular profiling of ER plus metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors.
Pedram Razavi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Genomic markers of early progression on fulvestrant with or without palbociclib for ER plus advanced breast cancer in the PALOMA-3 trial.
Ben O'Leary et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy
Aradhana Rani et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway
Xue Gao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
Jessica L. F. Teh et al.
CLINICAL CANCER RESEARCH (2019)
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer A Phase 1b Clinical Trial
Dejan Juric et al.
JAMA ONCOLOGY (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy
Erik S. Knudsen et al.
TRENDS IN CANCER (2019)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer
Mariko Kimura et al.
Oncotarget (2018)
Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial
Melanie Royce et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Mario Campone et al.
EUROPEAN JOURNAL OF CANCER (2018)
Investigation of Novel Regulation of N-myristoyltransferase by Mammalian Target of Rapamycin in Breast Cancer Cells
Marine Jacquier et al.
SCIENTIFIC REPORTS (2018)
Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
Tarah J. Ballinger et al.
FRONTIERS IN ONCOLOGY (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
R. Condorelli et al.
ANNALS OF ONCOLOGY (2018)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer
Paolo Pronzato
FUTURE ONCOLOGY (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Jose Baselga et al.
LANCET ONCOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity
Seraina Faes et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Nandini Dey et al.
PHARMACOLOGY & THERAPEUTICS (2017)
被撤回的出版物: Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells (Retracted article. See vol. 26, 2023)
Ludovica Taglieri et al.
ONCOLOGY LETTERS (2017)
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Erik S. Knudsen et al.
TRENDS IN CANCER (2017)
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC).
Gabriel N. Hortobagyi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies
Javier Cortes et al.
CANCER TREATMENT REVIEWS (2017)
Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells
Jacquelyn J. Bower et al.
NPJ BREAST CANCER (2017)
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR plus ) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
M. E. Cazzaniga et al.
BREAST (2017)
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2017)
INPP4B is an oncogenic regulator in human colon cancer
S. T. Guo et al.
ONCOGENE (2016)
Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation
Francesca De Iuliis et al.
TUMOR BIOLOGY (2016)
Targeting CDK4 and CDK6: From Discovery to Therapy
Charles J. Sherr et al.
CANCER DISCOVERY (2016)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
Targeting CDK4/6 in patients with cancer
Erika Hamilton et al.
CANCER TREATMENT REVIEWS (2016)
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
Cristian Massacesi et al.
ONCOTARGETS AND THERAPY (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al.
CANCER DISCOVERY (2016)
Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors
Seraina Faes et al.
ONCOTARGET (2016)
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial
Sarat Chandarlapaty et al.
JAMA ONCOLOGY (2016)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Marion Peyressatre et al.
CANCERS (2015)
Resistance to everolimus driven by epigenetic regulation of MYC in ER plus breast cancers
Teeru Bihani et al.
ONCOTARGET (2015)
PI3K mutations in breast cancer: prognostic and therapeutic implications
Toru Mukohara
BREAST CANCER-TARGETS AND THERAPY (2015)
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
M. Piccart et al.
ANNALS OF ONCOLOGY (2014)
Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions
Agnieszka K. Witkiewicz et al.
BREAST CANCER RESEARCH (2014)
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
Eva Maria Ciruelos Gil
CANCER TREATMENT REVIEWS (2014)
p16INK4a expression in retinoblastoma: a marker of differentiation grade
Yue Liu et al.
DIAGNOSTIC PATHOLOGY (2014)
Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Christine Fritsch et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
Denise A. Yardley et al.
ADVANCES IN THERAPY (2013)
Lessons from the dissection of the activation functions (AF-1 and AF-2) of the estrogen receptor alpha in vivo
Jean-Francois Arnal et al.
STEROIDS (2013)
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
Thomas Bachelot et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
The meaning of p16ink4a expression in tumors Functional significance, clinical associations and future developments
Agnieszka K. Witkiewicz et al.
CELL CYCLE (2011)
Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer
Carol A. Lange et al.
ENDOCRINE-RELATED CANCER (2011)
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
Chellappagounder Thangavel et al.
ENDOCRINE-RELATED CANCER (2011)
Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer
Jose Baselga
ONCOLOGIST (2011)
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
Todd W. Miller et al.
BREAST CANCER RESEARCH (2011)
Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
Josefine Bostner et al.
CLINICAL CANCER RESEARCH (2010)
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
The emerging mechanisms of isoform-specific PI3K signalling
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase
Ryaz B. Chagpar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Should individual PI3 kinase isoforms be targeted in cancer?
Shidong Jia et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Rb/Cdk2/Cdk4 triple mutant mice elicit an alternative mechanism for regulation of the G1/S transition
Weimin Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
分享论文
